Agoura Hills-based biotech firm Acelyrin Inc. agreed to merge with San Francisco-based Alumis Inc. in a deal valued at $320 ...

Alumis and Acelyrin have announced a definitive merger agreement, which will result in an all-stock transaction, creating a ...

The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the ...

Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.

Alumis is also developing another tyrosine kinase 2 blocker, A-005, for neuroinflammatory and neurodegenerative conditions ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

Alumis and Acelyrin have agreed to merge in an all-stock deal, creating a late-stage biopharmaceutical company focused on ...

Alumis Inc. SOUTH SAN FRANCISCO, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision ...

Alumis (ALUM) stock dropped while Acelyrin (SLRN) stock gained in the premarket as the biopharma companies announced an all-stock merger deal. Read more here.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Alumis Inc. (NASDAQ: ALMS) and ACELYRIN ...

Alumis (NASDAQ:ALMS – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Wednesday, February 12th. Analysts expect the company to announce earnings of ($1.36) ...